Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
Study Conducted by Dr. Vince Clinical ResearchKANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a...
Study Conducted by Dr. Vince Clinical ResearchKANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a...
Trust in individual healthcare providers depends largely on patients’ language preferences U.S. counties where provider trust is highest and lowest...
DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
16 total new listings added to the Sunday Market portfolio by February 20239 new Divvy products in profitable flower, vape,...
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as...
Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the...
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late...
LEXINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection...
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage,...
The latest recommendations from the U.S. Preventive Services Task Force (USPSTF) indicate that all adults under the age of 65...
Agreement is expected to optimize handling and shipment processes and reduce direct sales costs TEL AVIV, Israel, Nov. 01, 2022...
Activated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in...
Announces Restatements of Third Quarter 2021 and Full Year 2021 Financials Reports Select Preliminary Third Quarter 2022 Results CHARLOTTE, N.C.,...
NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing...
Cingal 19-01: Significant Reduction in WOMAC Pain from Baseline 19-01: Change in WOMAC Pain from Baseline (ITT)Study Demonstrated Superiority of...
Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty...
NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel...
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development...